Indication DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).

Rapidly reduced polyp burden as
early as week 4 and sustained
through 52 weeks1,2

DUPIXENT significantly reduced the size of nasal polyps, as measured by bilateral endoscopic NPS at Weeks 24 (coprimary endpoint) and 52 (secondary endpoint) in Trial 21

Before:
After DUPIXENT:
Right Nostril
Left Nostril
  • Illustrations of endoscopy adapted from actual patient images.
-2.24 Improvement

at Week 52 with DUPIXENT Q2W + INCS (n=150) (baseline score 6.07) vs
0.15 worsening with placebo + INCS (n=153) (baseline score 5.96) (LSM difference: -2.40 [95% CI: -2.77, -2.02]) in Trial 2

  • -1.71 Improvement in NPS at Week 24 with DUPIXENT Q2W + INCS (n=295, pooled DUPIXENT arms) (baseline score 6.18) vs 0.10 worsening with placebo + INCS (n=153) (baseline score 5.96) (LSM difference -1.80 [95% CI: -2.10, -1.51]) in Trial 21
    • NPS improved as early as Week 4 (LSM difference vs placebo: -1.15 [95% CI: -1.40, -0.91]) in Trial 21
  • -1.89 IMPROVEMENT IN NPS AT WEEK 24 with DUPIXENT Q2W + INCS (n=143) (baseline score 5.64) vs 0.17 worsening with placebo + INCS (n=133) (baseline score 5.86) (LSM difference: -2.06 [95% CI: -2.43, -1.69]) in Trial 12
  • Nasal polyps score (NPS), the sum of right and left nostril scores (range 0 to 8) as evaluated by nasal endoscopy: reduced score indicates improvement.
  • INCS, intranasal corticosteroids; LSM, least squares mean; Q2W, once every 2 weeks.

Identify CRSwNP
patients appropriate
for DUPIXENT

View Patients

References:

  1. Data on file, Sanofi US. LIBERTY NP SINUS-52, CSR. 2018.
  2. DUPIXENT Prescribing Information.